Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MetaVia ( (MTVA) ) just unveiled an update.
MetaVia Inc. has posted an updated corporate presentation detailing its ongoing efforts in developing next-generation therapeutics targeting obesity and MASH (Metabolic Associated Steatohepatitis). The company is focusing on increasing shareholder value through several upcoming milestones, including the DA-1726 Phase 1 trial for obesity and the DA-1241 Phase 2a trial for MASH, which has shown promising interim data. MetaVia is backed by strategic partner Dong-A ST and reported financial strength with $21.7 million in cash at the end of Q3 2024.
More about MetaVia
YTD Price Performance: 0.95%
Average Trading Volume: 130,832
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.35M
For an in-depth examination of MTVA stock, go to TipRanks’ Stock Analysis page.
